Befloxatone

Befloxatone is a monoamine oxidase inhibitor (MAOI) that was developed by Sanofi-Aventis for the treatment of depression. It acts by inhibiting the enzyme monoamine oxidase A (MAO-A), which breaks down serotonin, norepinephrine, and dopamine in the brain. By inhibiting this enzyme, befloxatone increases the levels of these neurotransmitters, which can help to alleviate the symptoms of depression.

History

Befloxatone was first synthesized in the 1990s by Sanofi-Aventis, a French multinational pharmaceutical company. It was developed as a potential treatment for depression, with the aim of providing a safer and more tolerable alternative to older MAOIs, which have significant side effects and dietary restrictions.

Pharmacology

Befloxatone is a selective and reversible inhibitor of MAO-A, an enzyme that degrades serotonin, norepinephrine, and dopamine in the brain. By inhibiting this enzyme, befloxatone increases the levels of these neurotransmitters, which can help to alleviate the symptoms of depression.

Clinical trials

Befloxatone has undergone several clinical trials to assess its efficacy and safety in the treatment of depression. However, the development of the drug was discontinued in the late 1990s due to concerns about its side effect profile.

Side effects

Like other MAOIs, befloxatone can cause a range of side effects, including nausea, dizziness, and insomnia. It can also cause a potentially dangerous increase in blood pressure if taken with certain foods or medications.

See also

• Monoamine oxidase inhibitor
• Depression
• Sanofi-Aventis

Befloxatone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia